Exact Sciences (EXAS) Competitors $46.71 +0.60 (+1.30%) Closing price 04:00 PM EasternExtended Trading$46.82 +0.12 (+0.25%) As of 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXAS vs. BIIB, INCY, UTHR, NBIX, BMRN, EXEL, MDGL, HALO, RGEN, and IONSShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Repligen (RGEN), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Exact Sciences vs. Its Competitors Biogen Incyte United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Madrigal Pharmaceuticals Halozyme Therapeutics Repligen Ionis Pharmaceuticals Biogen (NASDAQ:BIIB) and Exact Sciences (NASDAQ:EXAS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership. Is BIIB or EXAS more profitable? Biogen has a net margin of 15.31% compared to Exact Sciences' net margin of -34.19%. Biogen's return on equity of 13.85% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Exact Sciences -34.19%-1.75%-0.76% Do analysts prefer BIIB or EXAS? Biogen presently has a consensus price target of $185.74, indicating a potential upside of 36.21%. Exact Sciences has a consensus price target of $67.05, indicating a potential upside of 43.55%. Given Exact Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Exact Sciences is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34Exact Sciences 0 Sell rating(s) 3 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.91 Do insiders and institutionals have more ownership in BIIB or EXAS? 87.9% of Biogen shares are owned by institutional investors. Comparatively, 88.8% of Exact Sciences shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 1.2% of Exact Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, BIIB or EXAS? Biogen has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.07$1.63B$10.4613.04Exact Sciences$2.76B3.21-$1.03B-$5.43-8.60 Does the media prefer BIIB or EXAS? In the previous week, Biogen had 28 more articles in the media than Exact Sciences. MarketBeat recorded 46 mentions for Biogen and 18 mentions for Exact Sciences. Exact Sciences' average media sentiment score of 1.23 beat Biogen's score of 1.06 indicating that Exact Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 27 Very Positive mention(s) 3 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exact Sciences 14 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, BIIB or EXAS? Biogen has a beta of 0.13, indicating that its share price is 87% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. SummaryExact Sciences beats Biogen on 9 of the 17 factors compared between the two stocks. Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.84B$3.09B$5.74B$9.78BDividend YieldN/A2.26%4.40%4.04%P/E Ratio-8.6021.2230.8326.39Price / Sales3.21206.90382.9086.63Price / Cash8.1144.2437.7259.11Price / Book3.588.0710.106.62Net Income-$1.03B-$54.08M$3.26B$265.42M7 Day Performance-0.62%3.94%3.90%3.58%1 Month Performance-3.67%3.02%3.73%0.46%1 Year Performance-22.01%6.84%37.68%19.41% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.9353 of 5 stars$46.71+1.3%$67.43+44.4%-22.9%$8.84B$2.76B-8.607,000Positive NewsBIIBBiogen4.809 of 5 stars$135.91-1.9%$185.74+36.7%-33.3%$19.93B$9.68B12.997,605Positive NewsINCYIncyte4.6678 of 5 stars$84.92-2.3%$81.20-4.4%+28.9%$16.58B$4.24B19.302,617UTHRUnited Therapeutics4.9874 of 5 stars$314.10+0.3%$382.00+21.6%-10.8%$14.17B$2.88B12.261,305Positive NewsAnalyst RevisionNBIXNeurocrine Biosciences4.8625 of 5 stars$133.14+0.2%$160.90+20.9%-10.1%$13.20B$2.36B39.391,800News CoveragePositive NewsBMRNBioMarin Pharmaceutical4.9963 of 5 stars$57.44-0.2%$93.17+62.2%-36.2%$11.03B$2.85B17.043,040Positive NewsEXELExelixis4.8826 of 5 stars$37.76-1.4%$44.06+16.7%+49.0%$10.16B$2.17B18.151,147MDGLMadrigal Pharmaceuticals3.8643 of 5 stars$391.43+5.8%$439.71+12.3%+66.1%$8.69B$180.13M-30.4690Analyst ForecastHigh Trading VolumeHALOHalozyme Therapeutics4.6462 of 5 stars$68.96+2.5%$67.11-2.7%+17.3%$8.07B$1.02B15.78390News CoveragePositive NewsRGENRepligen4.8595 of 5 stars$124.08-0.2%$169.45+36.6%-17.8%$6.98B$673.96M-496.301,778Positive NewsIONSIonis Pharmaceuticals4.6222 of 5 stars$43.43-0.8%$59.38+36.7%-9.9%$6.92B$944.05M-23.601,069News CoverageAnalyst ForecastOptions VolumeAnalyst Revision Related Companies and Tools Related Companies Biogen Alternatives Incyte Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Exelixis Alternatives Madrigal Pharmaceuticals Alternatives Halozyme Therapeutics Alternatives Repligen Alternatives Ionis Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXAS) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access